文献速递临床血液与体液质量管理与危急值

基于生物学变异的六西格玛评分用于止血检测:适用于日常实践吗?

Determination of sigma score based on biological variation for haemostasis assays: fit-for-purpose for daily practice?
PubMed 文献 · Clin Chem Lab Med · 2019-01-01

三家实验室使用不同仪器和试剂,基于文献生物学变异数据结合内部和外部质控数据,计算凝血酶原时间、活化部分凝血活酶时间、纤维蛋白原和抗凝血酶的西格玛评分。结果显示西格玛评分范围宽泛,多数低于3.0,且已发表的生物学变异数据变异性大,六西格玛方法应用于生物学变异衍生的分析性能规范受到限制。

要点

  • 常见止血参数的西格玛评分相对较低,多数低于3.0。
  • 已发表的生物学变异数据变异性大,妨碍六西格玛方法的应用。
  • 许多止血试验仅用于诊断目的,需要适合目的的的分析性能规范。

核心结论

  • 常见止血参数的西格玛评分相对较低,且六西格玛方法应用于生物学变异衍生的分析性能规范受到已发表生物学变异数据大变异性的阻碍。

研究设计与样本

  • 三家使用不同仪器和试剂的实验室,计算凝血酶原时间、活化部分凝血活酶时间、纤维蛋白原和抗凝血酶的西格玛评分,使用文献生物学变异数据结合内部和外部质控数据。

主要发现

  • 当质控数据结合生物学变异数据的最小值、中位数和最大值时,凝血酶原时间的西格玛评分范围为0.1-6.8,活化部分凝血活酶时间为0.0-4.3,纤维蛋白原为1.5-8.3,抗凝血酶为0.1-2.4。
  • 应用生物学变异数据中位数时,内部质控数据下多数西格玛评分低于3.0,占75%;外部质控数据下占92%。

关键数值与推荐

  • 凝血酶原时间西格玛评分范围0.1-6.8,活化部分凝血活酶时间0.0-4.3,纤维蛋白原1.5-8.3,抗凝血酶0.1-2.4(结合生物学变异数据最小值、中位数和最大值)。
  • 应用生物学变异数据中位数时,内部质控数据下多数西格玛评分低于3.0(75%),外部质控数据下低于3.0(92%)。

临床怎么用

  • 基于生物学变异的六西格玛方法用于止血检测日常质控需谨慎,应考虑试验目的采用适合目的的分析性能规范。

局限性

  • 已发表的生物学变异数据变异性大,影响西格玛评分的可靠性。
  • 许多止血试验仅设计用于诊断目的,六西格玛概念基于监测要求,可能不适用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background Internal quality control (QC) rules for laboratory tests can be derived from analytical performance specifications (APS) using the six-sigma method. We tested the applicability of this paradigm to routine haemostasis measurements. Methods Three laboratories using different instruments and reagents calculated sigma scores for their prothrombin time (PT), activated partial thromboplastin time (APTT), fibrinogen and antithrombin (AT) measurements. Sigma scores were calculated using biological variation (BV) data from the literature in combination with internal and external QC data. Results Wide ranges in sigma scores for the PT (0.1-6.8), APTT (0.0-4.3), fibrinogen (1.5-8.3) and AT (0.1-2.4) were observed when QC data was combined with the minimum, median and maximum value of BV data, due in particular to a large variation in within-subject and between-subjects coefficients of variation. When the median BV values were applied, most sigma scores were below 3.0, for internal QC data; 75% and for external QC data; 92%. Conclusions Our findings demonstrate that: (1) The sigma scores for common haemostasis parameters are relatively low, and (2) The application of the six-sigma method to BV-derived APS is hampered by the large variation in published BV data. As the six-sigma concept is based on requirements for monitoring, and many haemostasis tests are only designed for diagnostic purposes, a fit-for-purpose APS is needed to achieve clinically relevant quality goals.

来源:Clin Chem Lab Med,查看原文。版权归原作者所有。

引用

  1. Hollestelle MJ, Ruinemans-Koerts J, Idema RN, et al. Determination of sigma score based on biological variation for haemostasis assays: fit-for-purpose for daily practice? Clin Chem Lab Med. 2019. PMID: 30838837. doi:10.1515/cclm-2018-0934

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。